An inhibitor-resistant ␤-lactamase (SHV-10), derived from an SHV-5 variant (SHV-9), was found in an Escherichia coli clinical isolate. In SHV-10, Ser-130 was replaced by Gly. The enzyme partially retained its ability to hydrolyze penicillins, but its activity against cephalosporins was drastically reduced. A Ser-1303Gly mutant of the prototype SHV-5, obtained by site-directed mutagenesis, had properties similar to those of SHV-10.
Studies have reported the emergence of class A ␤-lactamases resistant to mechanism-based inhibitors. The enzymes have been functionally classified as group 2br (5) and have evolved mostly from TEM-1 (2, 3, 8, 18) . A clavulanate-resistant laboratory mutant of the OHIO-1 ␤-lactamase of the SHV family has also been reported (4) . In the present work we describe an inhibitor-resistant enzyme (SHV-10) derived from the extended-spectrum ␤-lactamase (ESBL) variant SHV-9 that was previously reported as SHV-5a (17) .
The amoxicillin-clavulanate-resistant strain Escherichia coli CL55 was isolated from the urine of a hospitalized diabetic patient with a urinary tract infection. The patient had been treated with amoxicillin-clavulanate. E. coli K-12 14R525 (Nal r ) was used as the recipient in conjugation experiments. E. coli XL1-Blue (Stratagene) was used for transformation. Plasmid pAFF2 coding for SHV-5 (7), as well as plasmids pK318 and pEL-2K encoding SHV-9 (17), were also used. The phagemid pBCSK(ϩ) was used as a cloning vector. Clavulanate was from SmithKline Beecham, and tazobactam was a gift from Lederle. Nitrocefin was obtained from Oxoid. Other ␤-lactams were from commercial sources.
Conjugal transfer of ␤-lactam resistance was performed in mixed broth cultures by using E. coli 14R525 as the recipient. Susceptibility status was assessed by antibiograms, and MIC determinations were done by the E-test (Biodisk). For hydrolysis studies, crude enzyme preparations derived after ultrasonic treatment of bacterial suspensions were used. After removal of nucleic acids with streptomycin sulfate, the extracts were desalted and concentrated. The hydrolysis rates of the ␤-lactams were evaluated by UV spectrophotometry at 37ЊC and pH 7 as described previously (6) . Several substrate concentrations were used. The maximum rate of hydrolysis (V max ) and K m values were determined by using Lineweaver-Burk plots. The V max values were expressed as the rates of hydrolysis relative to that of penicillin G, which was set at 100. ␤-Lactamase activity was determined by using penicillin G as the substrate. One unit of ␤-lactamase activity was defined as the amount of enzyme that hydrolyzed 1 mol of penicillin G per min per mg of protein. To determine the inhibitory profiles of the enzymes, clavulanate, tazobactam, and aztreonam were used. The method that we followed was essentially that described previously (16) , with nitrocefin at a concentration of 50 M used as the substrate. Before the addition of the substrate, ␤-lactamases were incubated with the inhibitor for 5 min at 37ЊC and pH 7. The 50% inhibitory concentrations were determined from plots of the inhibitor concentration versus percent inhibition. Isoelectric focusing of ␤-lactamases was performed in polyacrylamide gels containing ampholytes (pH range, 3.5 to 9.5). For site-specific mutagenesis, a PCR-based method was followed (15) . Two pairs of primers were used, with one primer of each pair containing a single base mismatch to direct mutagenesis. The nucleotide sequences were determined by the dideoxy chain termination method with Sequenase version 2.0 (United States Biochemicals), and a set of universal and custom oligonucleotides.
The clinical E. coli strain, strain CL55, was resistant to penicillins and penicillin-inhibitor combinations but was susceptible to cephalosporins. The same ␤-lactam resistance pattern was transferred to E. coli 14R525 after conjugation ( Table 1) . The parent strain and the transconjugants harbored a 60-kbp plasmid, designated pAMC1, and expressed a ␤-lactamase with a pI of 8.2. A SmaI-ClaI fragment of 1.4 kbp from pAMC1 was cloned into pBCSK(ϩ). The resulting plasmid, pAMC3, was used to transform E. coli XL1-Blue cells and conferred a ␤-lactam resistance pattern similar to that of pAMC1. Preparations from both pAMC1 and pAMC3 hybridized strongly with an SHV-specific probe (data not shown). Determination of the nucleotide sequence of the SmaI-ClaI fragment of pAMC3 showed the presence of an SHV ␤-lactamase gene similar to that of the SHV-9 enzyme, previously reported as SHV-5a (17), except for an A3G transition that resulted in the substitution of Ser to Gly at codon 130 (1) of the mature ␤-lactamase. Other changes in the coding and promoter regions were not detected. The enzyme showed decreased hydrolytic activity against ␤-lactams compared with SHV-9. The changes in the K m values were more pronounced than those in the V max values ( Table 2 ). The enzyme was inhibited by 400-and 30-fold higher concentrations of clavulanate and tazobactam, respectively, compared with those required to inhibit SHV-9, and the enzyme was not inhibited by aztreonam (Table 3 ). This mutant ␤-lactamase was designated SHV-10. To ensure that this substitution was the sole cause of the observed phenotype, we constructed, by PCR site-directed mutagenesis, a Ser-1303 Gly mutant of the prototype SHV-5 (Fig. 1) . The final product was ligated to SmaI-ClaI-digested pBCSK(ϩ), resulting in plasmid pIRS5. The mutant enzyme conferred a resistance phenotype and displayed an inhibition profile and hydrolytic properties similar to those of SHV-10 (Tables 1 to 3 ).
The data presented above indicate that replacement of Ser-130 by Gly in SHV-5 confers resistance to ␤-lactamase inhibitors and drastically reduces the activity of the enzyme against ␤-lactam substrates. The role of the conserved Ser-130 residue in class A enzymes in the process of ␤-lactam binding and hydrolysis has been recognized. (i) Ser-130 participates in the maintenance of the geometry of the active site through its hydrogen bonding to Lys-234 (11); (ii) the Ser-130 side chain is involved in substrate recognition, interacting with the carboxylates of penicillins, cephalosporins, and ␤-lactamase inhibitors (9, 10, 12, 20) ; and (iii) Ser-130 either participates in the collapse of the tetrahedral intermediate by forming a hydrogen bond with the incipient amine in the course of Ser-70 acylation (9) or facilitates the transfer of a proton from Ser-70 to the ␤-lactam amine with the aid of Lys-73 (14, 19) .
Although the cephalosporinase activity of the SHV-10 enzyme was diminished, a residual activity against penicillin was observed. It appears that Ser-130 is more important in the initial interaction with cephalosporins. In its absence, the second hydrogen bond between Lys-234 and the cephalosporin molecule becomes stronger, thus impeding the proper alignment of the substrate in the active-site cavity (discussed by Juteau et al. [12] ).
The intensive use of penicillin-inhibitor combinations in the hospital setting and in the treatment of community-acquired infections may facilitate the sporadic appearance of enzymes like the one described here. However, their reduced activity, particularly against cephalosporins, may limit their spread.
Several class A, inhibitor-resistant, TEM-type-␤-lactamases have been described; changes of Met to Ile, Leu, or Val at position 69, Arg to Cys or Ser at position 244, and Asn to Asp at position 276 were reported in these cases. The amino acid substitutions listed above may influence the formation of the In the present work the significance of Ser-130 in both the hydrolysis of ␤-lactams and inactivation by the mechanismbased inhibitors has been confirmed in an ESBL derivative that belongs to the SHV family. It would be interesting to examine whether ESBLs of both the TEM and SHV types with mutations at positions 69, 244, and 276 can fully retain their activities against several ␤-lactam substrates.
